JP2022507812A5 - - Google Patents
Info
- Publication number
- JP2022507812A5 JP2022507812A5 JP2021527905A JP2021527905A JP2022507812A5 JP 2022507812 A5 JP2022507812 A5 JP 2022507812A5 JP 2021527905 A JP2021527905 A JP 2021527905A JP 2021527905 A JP2021527905 A JP 2021527905A JP 2022507812 A5 JP2022507812 A5 JP 2022507812A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- composition according
- alkylamino
- composition
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025010556A JP7805052B2 (ja) | 2018-11-20 | 2025-01-24 | 神経変性、筋変性及びリソソーム蓄積障害を治療するための組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769791P | 2018-11-20 | 2018-11-20 | |
| US62/769,791 | 2018-11-20 | ||
| PCT/US2019/062387 WO2020106825A1 (en) | 2018-11-20 | 2019-11-20 | Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025010556A Division JP7805052B2 (ja) | 2018-11-20 | 2025-01-24 | 神経変性、筋変性及びリソソーム蓄積障害を治療するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022507812A JP2022507812A (ja) | 2022-01-18 |
| JP2022507812A5 true JP2022507812A5 (enExample) | 2022-10-12 |
| JP7629200B2 JP7629200B2 (ja) | 2025-02-13 |
Family
ID=70774015
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021527905A Active JP7629200B2 (ja) | 2018-11-20 | 2019-11-20 | 神経変性、筋変性及びリソソーム蓄積障害を治療するための組成物及び方法 |
| JP2025010556A Active JP7805052B2 (ja) | 2018-11-20 | 2025-01-24 | 神経変性、筋変性及びリソソーム蓄積障害を治療するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025010556A Active JP7805052B2 (ja) | 2018-11-20 | 2025-01-24 | 神経変性、筋変性及びリソソーム蓄積障害を治療するための組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12246009B2 (enExample) |
| EP (1) | EP3883935A4 (enExample) |
| JP (2) | JP7629200B2 (enExample) |
| KR (1) | KR102902341B1 (enExample) |
| CN (2) | CN120040470A (enExample) |
| AU (1) | AU2019385480B2 (enExample) |
| CA (1) | CA3120639A1 (enExample) |
| IL (2) | IL283271B1 (enExample) |
| MX (2) | MX2021005875A (enExample) |
| WO (1) | WO2020106825A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3204868A1 (en) * | 2021-01-14 | 2022-07-21 | Charbel MOUSSA | Usp13 inhibitors and methods of use thereof |
| CN113713082B (zh) * | 2021-08-27 | 2023-07-18 | 福建医科大学 | 一种用于阿尔茨海默症的纳米自噬诱导剂及其制备方法与应用 |
| CN116626294B (zh) * | 2022-09-20 | 2024-07-09 | 菲创生物医学技术(广州)有限公司 | 盘状结构域受体2在诊断神经退行性疾病中的应用及相关的计算机可读介质 |
| US20240423995A1 (en) * | 2023-06-15 | 2024-12-26 | Georgetown University | C-kit inhibitors and uses for treating and preventing inflammatory conditions |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK6652000A3 (en) * | 1997-11-11 | 2002-05-09 | Pfizer Prod Inc | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| US6379666B1 (en) | 1999-02-24 | 2002-04-30 | Edward L. Tobinick | TNF inhibitors for the treatment of neurological, retinal and muscular disorders |
| EP1469810A4 (en) | 2002-01-04 | 2009-01-14 | Univ Rockefeller | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING BETA-AMYLOID PEPTIDE-RELATED DISORDERS |
| PT1478380E (pt) | 2002-02-27 | 2006-12-29 | Ab Science | Utilização de inibidores de tirosina-cinases para tratar doenças do snc |
| US7496357B2 (en) | 2002-03-04 | 2009-02-24 | At&T Intellectual Property I, L.P. | Automated telephone assistant device and associated methods |
| WO2004000313A2 (fr) | 2002-06-24 | 2003-12-31 | Exonhit Therapeutics Sa | Traitement de la sclerose laterale amyotrophique avec des composes modulateurs de l’activite de pgc-1 |
| ATE323702T1 (de) * | 2002-08-06 | 2006-05-15 | Astrazeneca Ab | Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität |
| US7595306B2 (en) | 2003-06-09 | 2009-09-29 | Alnylam Pharmaceuticals Inc | Method of treating neurodegenerative disease |
| GB0325031D0 (en) | 2003-10-27 | 2003-12-03 | Novartis Ag | Organic compounds |
| ES2415665T3 (es) | 2004-06-21 | 2013-07-26 | Proteome Sciences Plc | Procedimientos de cribado usando c-abl, fyn y sky en combinación con la proteína tau |
| EP1802321A4 (en) | 2004-09-03 | 2009-12-02 | Dana Farber Cancer Inst Inc | COMPOSITIONS AND METHOD FOR MODULATING PGC-1-ALPHA FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND ILLNESSES |
| WO2007056208A2 (en) * | 2005-11-02 | 2007-05-18 | Cytovia, Inc. | N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| US8003662B2 (en) | 2006-01-30 | 2011-08-23 | Array Biopharma, Inc. | Heterobicyclic thiophene compounds and methods of use |
| CA2651898A1 (en) * | 2006-04-07 | 2007-10-18 | Develogen Aktiengesellschaft | Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions |
| WO2007122634A2 (en) | 2006-04-24 | 2007-11-01 | Jubilant Biosys Limited | Pyrimidinediones as tyrosine kinase inhibitors |
| JP2010527614A (ja) | 2007-05-21 | 2010-08-19 | エラン・フアルマ・インターナシヨナル・リミテツド | パーキン基質およびアッセイ |
| EP2014663A1 (de) * | 2007-07-12 | 2009-01-14 | Bayer Schering Pharma AG | Thienopyrimidylamine als Modulatoren des EP2-Rezeptors |
| WO2009151683A2 (en) | 2008-03-12 | 2009-12-17 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
| US8618063B2 (en) | 2008-04-09 | 2013-12-31 | The Board Of Trustees Of The University Of Illinois | Method for treating a synucleinopathy |
| WO2010017541A2 (en) | 2008-08-08 | 2010-02-11 | The Johns Hopkins University | Compositions and methods for treatment of neurodegenerative disease |
| JP5690823B2 (ja) | 2009-07-08 | 2015-03-25 | レオ ファーマ アクティーゼルスカブ | Ｊａｋ受容体およびタンパク質チロシンキナーゼ阻害薬としての複素環化合物 |
| BR112012009094A8 (pt) | 2009-10-23 | 2017-10-10 | Novartis Ag | método de tratamento de transtornos proliferativos e outras condições patológicas mediadas por bcr-abl, c-kit, ddr1,ddr2 ou atividade pdgf-r quinase |
| JO3634B1 (ar) | 2009-11-17 | 2020-08-27 | Novartis Ag | طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r |
| CA2788835A1 (en) | 2010-02-05 | 2011-08-11 | The Administrators Of The Tulane Educational Fund | The use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with inhibitors of calcineurin or inhibitors of the mammalian target of rapamycin (mtor) complexes |
| EP2578590B1 (en) | 2010-05-26 | 2017-08-16 | Korea Institute of Science and Technology | Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases, and pharmaceutical composition containing same |
| WO2012042684A1 (ja) | 2010-10-01 | 2012-04-05 | パナソニック株式会社 | 脂質二重膜の表側から裏側にカリウムイオンを輸送する方法 |
| EP2665709B1 (en) | 2011-01-21 | 2016-12-07 | Sun Pharma Advanced Research Company Limited | Diarylacetylene hydrazide containing tyrosine kinase inhibitors |
| WO2013071264A1 (en) * | 2011-11-11 | 2013-05-16 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
| IN2014CN04558A (enExample) * | 2011-11-23 | 2015-09-18 | Cancer Rec Tech Ltd | |
| DK2844256T3 (da) | 2012-05-02 | 2023-03-27 | Univ Georgetown | Behandling af amyotrofisk lateral sklerose med tyrosinkinase-inhibitorer |
| EP2852388A4 (en) | 2012-05-23 | 2016-01-13 | Univ Johns Hopkins | COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
| JP6318156B2 (ja) * | 2012-09-06 | 2018-04-25 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | キナーゼをモジュレートするための化合物および方法、ならびにその指標 |
| HK1219421A1 (zh) * | 2013-03-15 | 2017-04-07 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
| US20160089371A1 (en) * | 2013-03-15 | 2016-03-31 | Intellikine, Llc | Combination of Kinase Inhibitors and Uses Thereof |
| WO2015051152A1 (en) | 2013-10-03 | 2015-04-09 | Leuvas Therapeutics | Modulation of leukocyte activity in treatment of neuroinflammatory degenerative disease |
| AU2016274956A1 (en) * | 2015-06-11 | 2017-12-14 | Usher Iii Initiative, Inc. | Methods of treating or preventing a proteopathy |
| JP2018525429A (ja) * | 2015-08-28 | 2018-09-06 | アッヴィ・インコーポレイテッド | Ｓ１ｐ調節剤としての縮合複素環化合物 |
| LT3463351T (lt) | 2016-06-02 | 2022-06-10 | Sun Pharma Advanced Research Company Limited | Parkinsono ligos gydymas |
| WO2018081777A1 (en) * | 2016-10-31 | 2018-05-03 | Georgetown University | Compositions and methods for treating neurodegenerative disorders |
| WO2018148533A1 (en) * | 2017-02-09 | 2018-08-16 | Georgetown University | Compositions and methods for treating lysosomal storage disorders |
| AU2018235446B2 (en) | 2017-03-15 | 2022-04-07 | Sun Pharma Advanced Research Company Limited | Novel amorphous dispersion of 4-Methyl-3-quinolin-3-ylethynyl-benzoic acid N'-(2-chloro-6-methyl-benzoyl) hydrazide |
-
2019
- 2019-11-20 CN CN202510189944.6A patent/CN120040470A/zh active Pending
- 2019-11-20 IL IL283271A patent/IL283271B1/en unknown
- 2019-11-20 US US17/295,553 patent/US12246009B2/en active Active
- 2019-11-20 IL IL327518A patent/IL327518A/en unknown
- 2019-11-20 JP JP2021527905A patent/JP7629200B2/ja active Active
- 2019-11-20 MX MX2021005875A patent/MX2021005875A/es unknown
- 2019-11-20 CA CA3120639A patent/CA3120639A1/en active Pending
- 2019-11-20 EP EP19887380.4A patent/EP3883935A4/en active Pending
- 2019-11-20 WO PCT/US2019/062387 patent/WO2020106825A1/en not_active Ceased
- 2019-11-20 CN CN201980087338.6A patent/CN113272308B/zh active Active
- 2019-11-20 AU AU2019385480A patent/AU2019385480B2/en active Active
- 2019-11-20 KR KR1020217018842A patent/KR102902341B1/ko active Active
-
2021
- 2021-05-19 MX MX2025000838A patent/MX2025000838A/es unknown
-
2025
- 2025-01-24 JP JP2025010556A patent/JP7805052B2/ja active Active
- 2025-02-07 US US19/048,131 patent/US20250177361A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6766198B2 (ja) | 細胞生存率を向上させるための組成物およびその使用方法 | |
| CA2530381C (fr) | Association d'un antagoniste ou agoniste inverse du recepteur h3 de l'histamine avec un anti-psychotique ou un antidepresseur et son utilisation pour preparer un medicament prevenant des effets indesirables de medicaments psychotropes | |
| US9790184B2 (en) | Inhibitors of histone deacetylase | |
| KR102220259B1 (ko) | Bace 매개 app 처리과정을 조절하는 히단토인 | |
| AU2010313255B2 (en) | The use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders | |
| US20240277673A1 (en) | Methods of treating behavior alterations | |
| KR101899613B1 (ko) | 염증 및 혈관 증식 관련 안 질환의 치료 방법 | |
| US10166204B2 (en) | Sphingosine kinase type 1 inhibitors and uses thereof | |
| US20140088145A1 (en) | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease | |
| JP2021001221A (ja) | 精神障害の治療における使用のためのイロペリドン代謝物 | |
| US20100179187A1 (en) | Indolone compounds useful to treat cognitive impairment | |
| CN103221043A (zh) | 用于治疗神经元连接发育障碍的erk抑制剂 | |
| JP2024149602A (ja) | 境界性パーソナリティ障害の処置方法 | |
| CN120837494A (zh) | 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法 | |
| US20070135509A1 (en) | Indolone compounds useful to treat cognitive impairment | |
| BR112021012102A2 (pt) | Regimes de dosagem para uso de ly3154207 no tratamento de distúrbios dopaminérgicos do snc | |
| US11426406B2 (en) | Compositions and methods for treating lysosomal storage disorders | |
| JPWO2008050600A1 (ja) | 酸化ストレス性細胞死を分子背景とする難治性疾患の治療または予防剤 | |
| Reddy et al. | Pharmacotherapy of Basal Ganglia Disorders: Parkinson Disease and Huntington Disease | |
| JP2024540241A5 (enExample) | ||
| TWI334349B (en) | Pain threshold reduction depressant | |
| JP2025518700A (ja) | グリシン輸送阻害剤を用いて肝性ポルフィリン症を処置するための組成物および方法 | |
| EP2241316A1 (en) | Indolone compounds useful to treat cognitive impairment | |
| HK1073243B (en) | Use of n-(indolecarbonyl-) piperazine derivatives | |
| HK1073243A1 (en) | Use of N-(indolecarbonyl-) piperazine derivatives |